Icecure Medical LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
IceCure Medical Ltd. received FDA marketing authorization for its ProSense system for low-risk breast cancer in women aged 70 and above, a significant regulatory milestone amidst ongoing financial challenges.
NASDAQ
20-F: IceCure Medical Reports FY2024 Results, Faces Going Concern Uncertainty Amidst Regulatory Review
IceCure Medical's FY2024 annual report reveals ongoing losses and doubts about its ability to continue as a going concern, while awaiting a critical FDA decision on its ProSense system for breast cancer treatment.
NASDAQ
20-F: IceCure Medical Reports FY2024 Results, Faces Going Concern Uncertainty Amidst Regulatory Review
IceCure Medical's FY2024 annual report reveals ongoing losses and doubts about its ability to continue as a going concern, while awaiting a critical FDA decision on its ProSense system for breast cancer treatment.
NASDAQ
20-F: IceCure Medical Establishes 2024 Employee Equity Incentive Plan and Files Annual Report on Form 20-F
IceCure Medical introduces a new employee equity incentive plan and files its annual report, highlighting its focus on cryoablation systems and technologies.